# QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis

> **NCT00581997** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 8 (actual)

## Conditions studied

- Pulmonary Fibrosis Secondary to Systemic Sclerosis

## Interventions

- **DRUG:** QAX576
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00581997
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-12
- **Primary completion:** 2009-04
- **Final completion:** —
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Concerns about risk of bronchoscopy procedure in the selected patient population and frequency of SAEs observed to date.
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00581997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00581997, "QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00581997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*